MetaCap

BioNTech (BNTX) vs Kymera Therapeutics (KYMR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kymera Therapeutics (KYMR) has outperformed BioNTech (BNTX) over the past year, gaining 74.6% versus a loss of 15.3%. Over five years, KYMR leads with a +114.4% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $9.84 billion), about 2.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTX-15.30%KYMR+74.61%
+117%+47%-22%
Nov 21, 20251 yearNov 20, 2026
BNTX-72.06%KYMR+87.50%
+124%+16%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTX versus KYMR key metrics
MetricBNTXKYMR
Share price$80.96$115.31
Market cap$20.07B$9.84B
1-day change-0.52%-3.42%
YTD return-14.96%+48.19%
1-year return-15.30%+74.61%
5-year return-76.74%+114.37%
EPS (TTM)$-6.83$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$39.21M
Revenue growth (YoY)—-16.70%
Net income (latest FY)—$-311.35M
Gross margin—0.00%
Operating margin—-891.07%
Net margin—-794.04%
52-week high$124.00$142.92
52-week low$79.52$63.69
Distance from 52-week high-34.71%-19.32%
Analyst consensusbuystrong_buy
Avg. price target upside+38.51%+25.94%
Average volume1.08M852.46K
Shares outstanding247.93M85.37M
Employees7,807285
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BioNTech is about 2.0 times larger than Kymera Therapeutics by market value ($20.07B vs $9.84B).
  • KYMR has outperformed BNTX by 89.9 percentage points over the past year.

About BioNTech

BNTX stock →

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees

About Kymera Therapeutics

KYMR stock →

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees

BNTX vs KYMR FAQ

Which is bigger, BioNTech or Kymera Therapeutics?

BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $9.84B for Kymera Therapeutics (KYMR).

Which stock has performed better over the past year, BNTX or KYMR?

KYMR returned +74.61% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.

Are BioNTech and Kymera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons